The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

Cost Control in a Parallel Universe: Medicare Spending in the United States and Canada

(2012) David U. Himmelstein et al.   ARCHIVES OF INTERNAL MEDICINE

Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

(2012) Xuelin Huang et al.   CANCER

Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008

(2011) Magnus Björkholm et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

(2011) Carlo Gambacorti-Passerini et al.   JNCI-Journal of the National Cancer Institute

Medical Bankruptcy in the United States, 2007: Results of a National Study

(2009) David U. Himmelstein et al.   AMERICAN JOURNAL OF MEDICINE

Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing

(2009) Bruce E. Hillner et al.   JOURNAL OF CLINICAL ONCOLOGY

How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question

(2009) T. Fojo et al.   JNCI-Journal of the National Cancer Institute

Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?

(2008) G J Ruiz-Argüelles et al.   BONE MARROW TRANSPLANTATION

An Empiric Estimate of the Value of Life: Updating the Renal Dialysis Cost-Effectiveness Standard

(2008) Chris P. Lee et al.   VALUE IN HEALTH